{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T02:22:06Z","timestamp":1790043726550,"version":"4.0.1"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Hematopoietic stem cell-based gene therapy offers the possibility of permanent correction for genetic disorders of the hematopoietic system. However, optimization of present protocols is required before gene therapy can be safely applied as general treatment of genetic diseases. In this study we have used a mouse model of type 1 Gaucher disease (GD) to demonstrate the feasibility of a low-risk conditioning regimen instead of standard radiation, which is associated with severe adverse effects. We first wanted to establish what level of engraftment and glucosylceramidase (GCase) activity is required to correct the pathology of the type 1 GD mouse. Our results demonstrate that a median wild-type (WT) cell engraftment of 7%, corresponding to GCase activity levels above 10 nmoles\/hour and mg protein, was sufficient to reverse pathology in bone marrow and spleen in the GD mouse. Moreover, we applied nonmyeloablative doses of busulfan as a pretransplant conditioning regimen and show that even WT cell engraftment in the range of 1%\u201310% can confer a beneficial therapeutical outcome in this disease model. Taken together, our data provide encouraging evidence for the possibility of developing safe and efficient conditioning protocols for diseases that require only a low level of normal or gene-corrected cells for a permanent and beneficial therapeutic outcome.<\/jats:p>","DOI":"10.1634\/stemcells.2008-0844","type":"journal-article","created":{"date-parts":[[2008,12,5]],"date-time":"2008-12-05T02:10:21Z","timestamp":1228443021000},"page":"744-752","source":"Crossref","is-referenced-by-count":34,"title":["Successful Low-Risk Hematopoietic Cell Therapy in a Mouse Model of Type 1 Gaucher Disease"],"prefix":"10.1093","volume":"27","author":[{"given":"Ida Berglin","family":"Enquist","sequence":"first","affiliation":[{"name":"Molecular Medicine and Gene Therapy, Institute of Laboratory Medicine and the Lund Strategic Research Center for Stem Cell Biology and Cell Therapy, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Nilsson","sequence":"additional","affiliation":[{"name":"Molecular Medicine and Gene Therapy, Institute of Laboratory Medicine and the Lund Strategic Research Center for Stem Cell Biology and Cell Therapy, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Eric","family":"M\u00e5nsson","sequence":"additional","affiliation":[{"name":"Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, Sahlgrenska University Hospital, M\u00f6lndal, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Ehinger","sequence":"additional","affiliation":[{"name":"Department of Pathology, Lund University Hospital, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Richter","sequence":"additional","affiliation":[{"name":"Molecular Medicine and Gene Therapy, Institute of Laboratory Medicine and the Lund Strategic Research Center for Stem Cell Biology and Cell Therapy, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Karlsson","sequence":"additional","affiliation":[{"name":"Molecular Medicine and Gene Therapy, Institute of Laboratory Medicine and the Lund Strategic Research Center for Stem Cell Biology and Cell Therapy, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,3,2]]},"reference":[{"key":"2022011221104907200_bib1","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1172\/JCI105417","article-title":"Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease","volume":"45","author":"Brady","year":"1966","journal-title":"J Clin Invest"},{"key":"2022011221104907200_bib2","first-page":"3635","volume-title":"The Metabolic and Molecular Bases of Inherited Disease","author":"Beutler","year":"2001","edition":"8th ed."},{"key":"2022011221104907200_bib3","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1073\/pnas.87.5.1913","article-title":"Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease","volume":"87","author":"Barton","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022011221104907200_bib4","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","article-title":"Replacement therapy for inherited enzyme deficiency\u2014Macrophage-targeted glucocerebrosidase for Gaucher's disease","volume":"324","author":"Barton","year":"1991","journal-title":"N Engl J Med"},{"key":"2022011221104907200_bib5","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0002-9343(02)01150-6","article-title":"Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: A report from the Gaucher Registry","volume":"113","author":"Weinreb","year":"2002","journal-title":"Am J Med"},{"key":"2022011221104907200_bib6","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1371\/journal.pmed.0010021","article-title":"Enzyme replacement in Gaucher disease","volume":"1","author":"Beutler","year":"2004","journal-title":"PLoS Med"},{"key":"2022011221104907200_bib7","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1126\/science.288.5466.669","article-title":"Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease","volume":"288","author":"Cavazzana-Calvo","year":"2000","journal-title":"Science"},{"key":"2022011221104907200_bib8","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1126\/science.1070104","article-title":"Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning","volume":"296","author":"Aiuti","year":"2002","journal-title":"Science"},{"key":"2022011221104907200_bib9","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(04)17590-9","article-title":"Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector","volume":"364","author":"Gaspar","year":"2004","journal-title":"Lancet"},{"key":"2022011221104907200_bib10","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/S0140-6736(08)60874-0","article-title":"Gene therapy of inherited diseases","volume":"371","author":"Fischer","year":"2008","journal-title":"Lancet"},{"key":"2022011221104907200_bib11","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1126\/science.1088547","article-title":"LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1","volume":"302","author":"Hacein-Bey-Abina","year":"2003","journal-title":"Science"},{"key":"2022011221104907200_bib12","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/sj.mt.6300060","article-title":"The genetic engineering of hematopoietic stem cells: The rise of lentiviral vectors, the conundrum of the ltr, and the promise of lineage-restricted vectors","volume":"15","author":"Chang","year":"2007","journal-title":"Mol Ther"},{"key":"2022011221104907200_bib13","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/nri1487","article-title":"Clinical strategies for expansion of haematopoietic stem cells","volume":"4","author":"Sorrentino","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"2022011221104907200_bib14","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1089\/hum.1998.9.17-2629","article-title":"Retroviral transfer of the glucocerebrosidase gene into CD34+ cells from patients with Gaucher disease: In vivo detection of transduced cells without myeloablation","volume":"9","author":"Dunbar","year":"1998","journal-title":"Hum Gene Ther"},{"key":"2022011221104907200_bib15","doi-asserted-by":"crossref","first-page":"13819","DOI":"10.1073\/pnas.0606016103","article-title":"Effective cell and gene therapy in a murine model of Gaucher disease","volume":"103","author":"Enquist","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022011221104907200_bib16","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/00007890-199307000-00034","article-title":"Hematopoietic cell transplantation in the twitcher mouse. The effects of pretransplant conditioning with graded doses of busulfan","volume":"56","author":"Yeager","year":"1993","journal-title":"Transplantation"},{"key":"2022011221104907200_bib17","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.1182\/blood-2002-06-1649","article-title":"Nonmyeloablative conditioning is sufficient to allow engraftment of EGFP-expressing bone marrow and subsequent acceptance of EGFP-transgenic skin grafts in mice","volume":"101","author":"Andersson","year":"2003","journal-title":"Blood"},{"key":"2022011221104907200_bib18","doi-asserted-by":"crossref","first-page":"16406","DOI":"10.1073\/pnas.0608130103","article-title":"Complete correction of murine Artemis immunodeficiency by lentiviral vector-mediated gene transfer","volume":"103","author":"Mostoslavsky","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022011221104907200_bib19","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.exphem.2007.05.009","article-title":"Low-dose parenteral busulfan provides an extended window for the infusion of hematopoietic stem cells in murine hosts","volume":"35","author":"Hsieh","year":"2007","journal-title":"Exp Hematol"},{"key":"2022011221104907200_bib20","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1182\/blood-2007-04-082602","article-title":"Hematopoietic stem-cell gene therapy of hemophilia A incorporating a porcine factor VIII transgene and nonmyeloablative conditioning regimens","volume":"110","author":"Ide","year":"2007","journal-title":"Blood"},{"key":"2022011221104907200_bib21","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nm1393","article-title":"Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1","volume":"12","author":"Ott","year":"2006","journal-title":"Nat Med"},{"key":"2022011221104907200_bib22","first-page":"2338","article-title":"Differential effects of cytotoxic agents on hematopoietic progenitors","volume":"41","author":"Botnick","year":"1981","journal-title":"Cancer Res"},{"key":"2022011221104907200_bib23","first-page":"913","article-title":"Transient and permanent engraftment potential of murine hematopoietic stem cell subsets: Differential effects of host conditioning with gamma radiation and cytotoxic drugs","volume":"21","author":"Down","year":"1993","journal-title":"Exp Hematol"},{"key":"2022011221104907200_bib24","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1182\/blood-2003-08-2935","article-title":"The impact of low-dose busulfan on clonal dynamics in nonhuman primates","volume":"104","author":"Kuramoto","year":"2004","journal-title":"Blood"},{"key":"2022011221104907200_bib25","doi-asserted-by":"crossref","first-page":"8263","DOI":"10.1016\/S0021-9258(19)83905-4","article-title":"Human acid beta-glucosidase. Use of conduritol B epoxide derivatives to investigate the catalytically active normal and Gaucher disease enzymes","volume":"261","author":"Grabowski","year":"1986","journal-title":"J Biol Chem"},{"key":"2022011221104907200_bib26","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1073\/pnas.87.6.2334","article-title":"Correction of glucocerebrosidase deficiency after retroviral-mediated gene transfer into hematopoietic progenitor cells from patients with Gaucher disease","volume":"87","author":"Fink","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022011221104907200_bib27","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/j.1651-2227.1990.tb11492.x","article-title":"Rapidly progressive type III Gaucher disease: Deterioration following partial splenectomy","volume":"79","author":"Kyllerman","year":"1990","journal-title":"Acta Paediatr Scand"},{"key":"2022011221104907200_bib28","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/BF03401556","article-title":"Failure of alglucerase infused into Gaucher disease patients to localize in marrow macrophages","volume":"1","author":"Beutler","year":"1995","journal-title":"Mol Med"},{"key":"2022011221104907200_bib29","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1023\/B:BOLI.0000042959.44318.7c","article-title":"Correlation between enzyme activity and substrate storage in a cell culture model system for Gaucher disease","volume":"27","author":"Schueler","year":"2004","journal-title":"J Inherit Metab Dis"},{"key":"2022011221104907200_bib30","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1182\/blood-2004-07-2648","article-title":"Clonal evidence for the transduction of CD34+ cells with lymphomyeloid differentiation potential and self-renewal capacity in the SCID-X1 gene therapy trial","volume":"105","author":"Schmidt","year":"2005","journal-title":"Blood"},{"key":"2022011221104907200_bib31","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1172\/JCI30953","article-title":"Gene therapy for severe combined immunodeficiency: Are we there yet?","volume":"117","author":"Cavazzana-Calvo","year":"2007","journal-title":"J Clin Invest"},{"key":"2022011221104907200_bib32","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/sj.bmt.1703613","article-title":"Selective growth advantage of wild-type lymphocytes in X-linked SCID recipients","volume":"30","author":"Kume","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"2022011221104907200_bib33","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1126\/science.1149726","article-title":"Efficient transplantation via antibody-based clearance of hematopoietic stem cell niches","volume":"318","author":"Czechowicz","year":"2007","journal-title":"Science"},{"key":"2022011221104907200_bib34","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.stem.2007.10.020","article-title":"Thrombopoietin\/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche","volume":"1","author":"Yoshihara","year":"2007","journal-title":"Cell Stem Cell"}],"container-title":["Stem Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1634%2Fstemcells.2008-0844","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/stemcells.2008-0844","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/stemcells.2008-0844","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/stmcls\/article-pdf\/27\/3\/744\/41947100\/stmcls_27_3_744.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/stmcls\/article-pdf\/27\/3\/744\/41947100\/stmcls_27_3_744.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T02:56:37Z","timestamp":1642560997000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/stmcls\/article\/27\/3\/744-752\/6401906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,1]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2009,3,2]]},"published-print":{"date-parts":[[2009,3,1]]}},"URL":"https:\/\/doi.org\/10.1634\/stemcells.2008-0844","relation":{},"ISSN":["1066-5099","1549-4918"],"issn-type":[{"value":"1066-5099","type":"print"},{"value":"1549-4918","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2009,3,1]]},"published":{"date-parts":[[2009,3,1]]}}}